Jasper Therapeutics, Inc. (JSPR)
Automate Your Wheel Strategy on JSPR
With Tiblio's Option Bot, you can configure your own wheel strategy including JSPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JSPR
- Rev/Share 0.0782
- Book/Share 1.5644
- PB 1.5595
- Debt/Equity 0.0917
- CurrentRatio 2.0959
- ROIC -3.3686
- MktCap 39653020.0
- FreeCF/Share -6.4132
- PFCF -0.4116
- PE -0.5709
- Debt/Assets 0.0464
- DivYield 0
- ROE -1.2165
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JSPR | BMO Capital Markets | Outperform | Market Perform | -- | $4 | July 8, 2025 |
| Downgrade | JSPR | RBC Capital Mkts | Outperform | Sector Perform | -- | $5 | July 8, 2025 |
| Downgrade | JSPR | William Blair | Outperform | Market Perform | -- | -- | July 7, 2025 |
| Downgrade | JSPR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | July 7, 2025 |
| Initiation | JSPR | UBS | -- | Buy | -- | $38 | Feb. 13, 2025 |
| Initiation | JSPR | BMO Capital Markets | -- | Outperform | -- | $63 | Dec. 6, 2024 |
| Initiation | JSPR | JMP Securities | -- | Mkt Outperform | -- | $70 | Sept. 9, 2024 |
News
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”).
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Jasper Therapeutics, Inc. (JSPR) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Jasper's business, operations, and compliance policies, including allegations that: (i) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (ii) the foregoing failure increased the risk that results of ongoing studies …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: August 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: August 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in …
Read More
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update.
Read More
About Jasper Therapeutics, Inc. (JSPR)
- IPO Date 2020-01-10
- Website https://jaspertherapeutics.com
- Industry Biotechnology
- CEO Ronald A. Martell
- Employees 64